Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Jorge Conde, James Evans

Premium

Knome's Co-founder Jorge Conde has joined Syros Pharmaceuticals as CFO and chief product officer where he will lead the platform strategy for Syros' novel gene regulation technology and manage the overall finances for the company. Conde most recently served as Knome's CFO, but has also worked in marketing and operations at MedImmune, as well as at Helicos Biosciences. Previously, he was an investment banker at Morgan Stanley.


Myriad's CFO James Evans has retired, but will continue to serve as CFO until the company finds a replacement. He joined Myriad in 1995 as a corporate controller and was promoted to vice president of finance in 2005. In 2007, he was named CFO.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.